SYM FINANCIAL Corp Takes Position in Humana Inc. (NYSE:HUM)

SYM FINANCIAL Corp bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 875 shares of the insurance provider's stock, valued at approximately $222,000.

Other large investors have also recently modified their holdings of the company. Creative Financial Designs Inc. ADV increased its stake in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana during the 3rd quarter valued at $29,000. Ashton Thomas Securities LLC bought a new position in Humana in the third quarter valued at about $31,000. Your Advocates Ltd. LLP grew its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock valued at $32,000 after buying an additional 45 shares during the period. Finally, LRI Investments LLC grew its holdings in Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider's stock valued at $50,000 after purchasing an additional 143 shares during the period. Institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Humana from $288.00 to $301.00 and gave the company an "equal weight" rating in a research note on Tuesday, December 17th. Barclays raised their target price on shares of Humana from $253.00 to $255.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 22nd. Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research report on Monday, January 6th. KeyCorp assumed coverage on Humana in a report on Friday, October 11th. They set a "sector weight" rating on the stock. Finally, Sanford C. Bernstein upgraded Humana from a "market perform" rating to an "outperform" rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $297.68.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.29% of the stock is owned by company insiders.

Humana Price Performance

Shares of NYSE:HUM traded down $5.02 during midday trading on Wednesday, reaching $290.52. 1,102,481 shares of the company's stock traded hands, compared to its average volume of 1,506,451. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a fifty day simple moving average of $275.13 and a two-hundred day simple moving average of $299.72. The company has a market cap of $34.98 billion, a P/E ratio of 25.73, a PEG ratio of 2.21 and a beta of 0.56.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.